Latest Health News

Amplia Therapeutics and ANZGOG have initiated a clinical trial to test narmafotinib combined with chemotherapy in ovarian cancer patients unresponsive to platinum-based treatment, aiming to improve surgical outcomes and explore biomarker insights.

AMA Group has initiated an on-market share buy-back program for up to 47.8 million shares, signalling confidence in its financial position and growth strategy without needing shareholder approval.

QBE Insurance Group kicked off 2026 with robust premium growth and solid underwriting, maintaining its full-year guidance amid geopolitical uncertainty and evolving risks.

BPH Global inks binding deal with Temasek Innovation Holdings to validate its seaweed-based male vitality product through targeted biological assays, advancing regulatory and commercial ambitions.

Xenitra Limited has secured $1.25 million through a share placement to accelerate its OTC medicines rollout and expand its OPAL RWA token ecosystem, with shareholder approval pending for attached options.

Boom Logistics has upgraded its FY26 earnings guidance, anticipating a 31% rise in statutory EPS, backed by $7 million in new contracts across energy and mining sectors.

Amcor posted a 77% jump in Q3 net sales fueled by the Berry acquisition, delivering synergy gains above expectations and updating fiscal 2026 guidance amid geopolitical headwinds.

Careteq Limited has cleared $125,000 in director and company secretary loans a month ahead of schedule, using proceeds from a recent $2.2 million capital raising. This move strengthens the healthtech firm’s balance sheet and removes related-party debt ahead of maturity.

Judo Bank’s Q3 results show solid lending expansion, stable credit quality amid economic uncertainty, and reaffirmed FY26 guidance with a healthy capital buffer.

Resonance Health upgrades its FY26 underlying EBITDA guidance to $2.6 million, driven by operational efficiencies and growth in its Software-as-Medical Devices segment, despite a slight revenue timing delay.

Beamtree Holdings has landed a $2 million contract with Saudi Arabia’s Fakeeh Care Group, while revising down its FY26 ARR growth guidance and outlining cost-cutting measures as part of an ongoing strategic review.

Emyria Limited reported $1.2 million in revenue for the March quarter, driven by insurer-funded clinics and strong clinical outcomes in PTSD treatment. The company is advancing its national clinic rollout, including new sites in Victoria and New South Wales, while launching a global partnership program targeting international drug sponsors.